Conrad Achilonu
Researcher
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Introduction Carbapenem-resistant Pseudomonas aeruginosa (CRPA) represents a global threat, but the global distribution of carbapenem resistant bacteria remains a critical issue in public health. Methods We conducted a systematic review and meta-analysis on the global pooled prevalence estimate (PPE) of CRPA and their antibiotic resistance. The systematic review protocol was registered with PROSPERO (CRD42024579654). This study was carried out following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Heterogeneity between studies was assessed using Cochrane Q test and I 2 test statistics based on the random effects model. Comprehensive meta-analysis software v4.0 was used to analyze the pooled prevalence of CRPA. Results A total of 163 studies (both clinical and screening samples) containing a total of 58,344 cases from 39 countries were included in this study. The overall PPE of CRPA was 34.7% (95% CI: 0.316–0.37.8) for both clinical and screening samples. Meropenem had a PPE of 31.2% (95% CI: 0.272–0.352) and imipenem had the lowest PPE of 27.7% (95% CI: 0.238–0.319). Japan had the highest PPE at 98.2% (95% CI: 0.482–0.100) of CRPA, and the lowest was observed for Saudi Arabia at 13.9% (95% CI: 0. 064–0. 277). CRPA is widespread on five continents except Australia and Antarctica, while the highest PPE is in Europe at 47.6% (95% CI: 0.359–0.595) and the lowest in Asia at 32, 8% (95% CI: 0.293–0.364). The relatively higher PPE of CRPA was observed in Europe during the year interval 2014–2017 at 95.4% (95% CI: 0.388–0.999), followed by Africa from the year 2022–2024 with 38.5% (95% CI: 0.243–0.550). Ceftazidime was significantly higher in studies conducted before 2019 with a PPE of 44.7% (95% CI: 0.246% – 0.668), while CRPA after 2019 had a higher resistance to cefoperazone/sulbactam with a PPE of 17.3% (95% CI: 0.050–0.455). Discussion This review indicates that the prevalence of CRPA is generally high and varies significantly between countries. To prevent the emergence of CRPA and antibiotic resistance, future initiatives should prioritise strengthening laboratory capacity for early detection of antibiotic resistance.
Year:
2025
Purpose of Review Cholangiocarcinoma (CCA) is the most lethal and common malignant tumours that occur in the bile ducts. Although it is relatively rare, it is prevalent with an annual incidence rate of 0.3–6% per 100,000 people globally. The onset of CCA can be influenced by several risk factors, including exposure to invasive fungal pathogens. Immunocompromised patients with CCA that undergo endoscopic retrograde cholangiopancreatography (ERCP) are susceptible to invasive fungal infections (IFIs) caused by the World Health Organization (WHO) priority list of critical fungal pathogens. This potentially leads to harbouring of antifungal-drug resistant pathogens (AFDRPs) that could have a detrimental impact on disease treatment as a result of their resistance mechanisms. Recent Findings In this article, we reviewed the prevalence and impact of AFDRP colonisation in CCA patients undergoing ERCP. The potential influence of AFDRPs on the development of CCA tumours or the response to treatment. Lastly, we addressed the potential application of drug delivery systems based on nanoparticles for the targeted delivery of antifungal and anticancer agents to AFDRPs in CCA patients. Summary Understanding the mechanisms of nanoparticles (NPs) in manipulating fungal cells and CCA cells as these interactions are complex. Therefore, the development effective NP-based strategies as antifungal and anticancer agents in important for the treatment of cancer and fungal infections.
Year:
2025
Year:
2024
Cetaceans, which are crucial in marine ecosystems, act as sentinels for ecosystem and human–environmental health. However, emerging fungal infections, particularly by Candida spp., pose a growing concern in these marine mammals. This review consolidates current knowledge on the prevalence, clinical manifestations, species distribution, and antifungal resistance of Candida infections in cetaceans. We detail the diverse pathogenic impacts of Candida, including respiratory, dermal, and systemic afflictions, underscoring diagnostic and treatment challenges amid rising antifungal resistance. Our analysis extends beyond health concerns in captive cetaceans, where confinement stress heightens vulnerability, to encompass substantial ecological risks in wild populations. The review emphasizes the One Health perspective, linking cetacean health with broader environmental and human public health issues. We particularly focus on the potential zoonotic transmission of emerging fungal pathogens such as Candida auris and the role of environmental changes in fostering antifungal resistance. The study underscores the need for concerted, interdisciplinary efforts in veterinary, medical, and environmental sciences to enhance understanding and management of Candida infections in cetaceans. We advocate for comprehensive monitoring and collaborative research initiatives to mitigate the rising challenge of these infections. Addressing Candida spp. in cetaceans is not just a conservation priority but a critical step in safeguarding overall marine health and, by extension, human health in the context of evolving infectious diseases.
Year:
2024
(1) Background: In recent years, a global epidemiological shift in candidemia has been observed, marked by the emergence of resistant non-albicans Candida species. Candida auris, in particular, has become a significant global concern, causing infections in both pediatric and adult populations within healthcare settings. Despite its widespread impact, there is a limited understanding of the clinical course and transmission dynamics of neonatal systemic Candida auris infections, hindering effective prevention and management. This study focused on the epidemiologic data, the clinical presentation, risk factors, and outcome of C. auris infection in neonatal population. (2) Methods: A systematic review of the literature using PubMed and Scopus databases until December 2023 was conducted. (3) Results: A total of 24 relevant studies were identified, encompassing 476 documented cases of Candida auris infection in neonates. Prematurity emerged as a primary risk factor, alongside total parenteral nutrition, central line insertion, mechanical ventilation, and prior broad-spectrum antibiotic use. The mortality rate reached approximately 42%, with therapeutic details sparingly reported in 12% of cases. Treatment strategies varied, with amphotericin B predominantly used as monotherapy, while combination antifungal agents were used in 44% of cases. Notably, 97.4% of cases exhibited fluconazole resistance, and 67.1% showed resistance to amphotericin B. Limited data were available on resistance to other antifungal agents. (4) Conclusions: Despite the rarity of neonatal Candida auris infections, their global occurrence necessitates comprehensive preparedness in patient care. A deeper understanding of Candida auris pathogenesis is crucial for developing effective strategies to control and prevent neonatal infections caused by this pathogen.
Year:
2024
The World Health Organization has established a fungal priority pathogens list that includes species critical or highly important to human health. Among them is the order Mucorales, a fungal group comprising at least 39 species responsible for the life-threatening infection known as mucormycosis. Despite the continuous rise in cases and the poor prognosis due to innate resistance to most antifungal drugs used in the clinic, Mucorales has received limited attention, partly because of the difficulties in performing genetic manipulations. The COVID-19 pandemic has further escalated cases, with some patients experiencing the COVID-19-associated mucormycosis, highlighting the urgent need to increase knowledge about these fungi. This review addresses significant challenges in treating the disease, including delayed and poor diagnosis, the lack of accurate global incidence estimation, and the limited treatment options. Furthermore, it focuses on the most recent discoveries regarding the mechanisms and genes involved in the development of the disease, antifungal resistance, and the host defense response. Substantial advancements have been made in identifying key fungal genes responsible for invasion and tissue damage, host receptors exploited by the fungus to invade tissues, and mechanisms of antifungal resistance. This knowledge is expected to pave the way for the development of new antifungals to combat mucormycosis. In addition, we anticipate significant progress in characterizing Mucorales biology, particularly the mechanisms involved in pathogenesis and antifungal resistance, with the possibilities offered by CRISPR-Cas9 technology for genetic manipulation of the previously intractable Mucorales species.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (12)
Shunsuke Kondo
Professor
Tokyo Women's Medical University
Taroh Satoh
Professor
Osaka University Hospital
Begoña Acosta-Hernández
Universidad de Las Palmas de Gran Canaria
Zoi Iliodromiti
National and Kapodistrian University of Athens
Eusebio Navarro
Universidad de Murcia
Satoshi Kobayashi
Kanagawa Cancer Center
Changhoon Yoo
University of Ulsan College of Medicine
Guilhem Janbon
Head of Unit
Institut Pasteur
Hugh Gifford
NIHR Clinical Lecturer
University of Exeter
Mª Inmaculada Rosario Medina
Profesora
Universidad de Las Palmas de Gran Canaria
Yoshito Komatsu
Hokkaido University Hospital
Victoriano Garre
Professor
Universidad de Murcia
Make your next move.
Prepare your application
Review drafts before you send them.